Aligos Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Aligos Therapeutics

01/11/2023 02:05

* Aligos Therapeutics Inc  ALGS.OQ   ALGS.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 39.1% decrease in revenue to $2.5 million from $4.11
million a year ago, according to the mean estimate from 2
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Aligos Therapeutics
Inc
is for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3​, above​ its last closing price of $0.60.
​​​

This summary was machine generated November 1 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated